BMEA vs KYMR vs ARVN vs VYNE vs IMVT

For growth investors, VYNE Therapeutics Inc.

(VYNE) is the stronger pick with 13. 8% revenue growth year-over-year, versus -16. 7% for Kymera Therapeutics, Inc. (KYMR). Analysts rate Biomea Fusion, Inc. (BMEA) a "Buy" — based on 13 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Immunovant, Inc.

(IMVT) delivered a total return of +213. 0%, compared to -99. 1% for VYNE Therapeutics Inc. (VYNE). Over 10 years, the gap is even starker: IMVT returned +237. 9% versus VYNE's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), VYNE Therapeutics Inc.

(VYNE) is the lower-risk stock at 0. 75β versus Biomea Fusion, Inc. 's 1. 78β — meaning BMEA is approximately 137% more volatile than VYNE relative to the S&P 500. On balance sheet safety, Immunovant, Inc. (IMVT) carries a lower debt/equity ratio of 0% versus 5% for Biomea Fusion, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), VYNE Therapeutics Inc.

(VYNE) is pulling ahead at 13. 8% versus -16. 7% for Kymera Therapeutics, Inc. (KYMR). On earnings-per-share growth, the picture is similar: Biomea Fusion, Inc. grew EPS 69. 2% year-over-year, compared to -23. 8% for Kymera Therapeutics, Inc.. Over a 3-year CAGR, ARVN leads at 26. 0% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Biomea Fusion, Inc.

(BMEA) is the more profitable company, earning 0. 0% net margin versus -46. 5% for VYNE Therapeutics Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: BMEA leads at 0. 0% versus -52. 2% for VYNE. At the gross margin level — before operating expenses — KYMR leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Kymera Therapeutics, Inc.

(KYMR) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 91), +159. 2% 10Y return). Biomea Fusion, Inc. (BMEA) carries a higher beta of 1. 78 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (KYMR: +159. 2%, BMEA: -93. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.